As such, drug repurposing offers a more effective strategy that suits the urgency of the need for treatments of COVID-19. While current efforts to develop new medicines through generative approaches for the COVID-19 outbreak can result in possible therapies, new drug development efforts can be resource intensive and require a number of years of both pre-clinical and clinical testing. Renowned Chinese medical research institution in Beijing, Institute of Materia Medica, Chinese Academy of Medical Sciences, enters a strategic collaboration with Canadian-based biotechnology company Cyclica to discover antiviral drug candidates for COVID-19 and explore opportunities to design multi-targeted antiviral compounds. This rapid widespread has made more countries realize the need for international collaboration to address this global concern. TORONTO & BEIJING-( BUSINESS WIRE)-The epidemic of COVID-19 remains a prominent healthcare challenge, affecting more than 70 countries and regions over the world.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |